SCHEMBL4097686

SCHEMBL4097686

Oc1cc2ccncc2c2cc(F)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
CHUK O15111 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41
KDM4E B2RXH2 3/20 0.40
HTT P42858 2/20 0.40
POLB P06746 1/20 0.40
RAD52 P43351 1/20 0.40
MAPK10 P53779 1/20 0.39
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39
KAT8 Q9H7Z6 1/20 0.39
DAO P14920 2/20 0.38
P4HB P07237 1/20 0.38
GRM4 Q14833 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.37
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
TDO2 P48775 2/20 0.36
TRPM4 Q8TD43 1/20 0.36
MAPKAPK2 P49137 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22490163 0.79 HIPK2 (0.53) ACHECHUKHIPK2KDM4EHTT
SCHEMBL1397330 0.71 NQO2 (0.52) HIPK2KDM4EHTTPOLBRAD52
SCHEMBL2501659 0.71 TOP2A (0.45) ACHEHIPK2KDM4EHTTPOLB
SCHEMBL9827753 0.71 DAO (0.44) HIPK2KDM4EHTTPOLBRAD52
SCHEMBL23557738 0.69 CHUK (0.47) ACHECHUKHIPK2KDM4EHTT
SCHEMBL2505316 0.68 KDM4E (0.41) ACHEHIPK2KDM4EHTTPOLB
SCHEMBL25625877 0.68 CHUK (0.46) ACHECHUKHIPK2KDM4EHTT
SCHEMBL15495286 0.68 TOP2A (0.43) ACHEHIPK2KDM4EHTTPOLB
SCHEMBL28242113 0.68 MAOA (0.42) ACHEHIPK2KDM4EHTTPOLB
SCHEMBL22513859 0.67 DAO (0.41) HIPK2KDM4EHTTPOLBRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 US disclosed
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 ACHE 4858/4885CHUK 36/4885HIPK2 596/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 ACHE 4858/4885CHUK 36/4885HIPK2 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.